More recently, a CD38-targeted immune PET tracer, [89Zr]daratumumab, has successfully been synthetized and demonstrated tracer uptake at myeloma sites that were occult at routine MM imaging modalities [118]. The gene discussed is CD38; the disease is Miyoshi myopathy.